|
Development of drug resistance in colon cancer patients following chemotherapy, a contributing factor in the failure of oxaliplatin-based HIPEC to improve survival in the Prodige 7 trial. |
| |
|
Employment - Nagourney Cancer Institute |
Leadership - Nagourney Cancer Institute |
Patents, Royalties, Other Intellectual Property - Metabolomycs |
| |
|
Employment - Nagourney Cancer Institute |
Leadership - Nagourney Cancer Institute |
| |
|
Employment - Nagourney Cancer Institute |
| |
|
No Relationships to Disclose |
| |
|
Employment - Nagourney Cancer Institute |
| |
|
Employment - Nagourney Cancer Institute |
| |
|
Employment - MedStar Washington Hospital Center |
Leadership - MedStar Washington Hospital Center |